Key Highlights

  • Loss per share was USD 0.39 against an estimate of a USD 0.35 loss.
  • Research and development expense was USD 48.9 million, against USD 30.8 million.
  • General and administrative expense was USD 29.2 million, against USD 8.9 million.
  • Cash and marketable securities were USD 977.5 million at September 30.

Tango Therapeutics (NASDAQ:TNGX) reported a third quarter 2026 loss per share of USD 0.39, against an estimate of a USD 0.35 loss. The company reported a loss before income taxes of USD 68.39 million, compared with income before income taxes of USD 15.87 million in the third quarter of 2025.

Total operating expenses were USD 78.12 million, against USD 39.74 million a year earlier. The company reported an operating loss of USD 78.12 million, compared with Operating Income of USD 14.07 million in the prior-year quarter.

Research and Administrative Expenses

Research and development expense was USD 48.9 million for the three months ended September 30, 2026, compared with USD 30.8 million for the same period in 2025. General and administrative expense was USD 29.2 million, compared with USD 8.9 million.

For the nine months, total operating expenses were USD 186.67 million, against USD 131.81 million. The operating loss for the nine months was USD 186.67 million, compared with USD 69.43 million, and the loss before income taxes was USD 169.25 million, against USD 62.79 million.

Interest and Other Income

Interest income was USD 7.2 million for the quarter and USD 13.05 million for the nine months, compared with USD 1.1 million a year earlier, with the increase primarily attributable to a higher marketable securities balance during the third quarter of 2026. Other income, net was USD 2.6 million, against USD 0.7 million.

The filing shows no income tax provision for the quarter, compared with a benefit of USD 10,000 in the prior-year quarter. Total other income, net was USD 9.72 million, compared with USD 1.80 million in the third quarter of 2025. For the nine months, total other income, net was USD 17.42 million, against USD 6.64 million.

Liquidity and Collaboration Background

The company said its existing cash, cash equivalents and marketable securities of USD 977.5 million as of September 30, 2026 are sufficient to meet its current operating plan and fund operating expenses and Capital Expenditure requirements for at least twelve months from the issuance date of the financial statements.

The filing describes an October 2025 underwritten offering and concurrent private Placement of 22,755,438 shares of common stock at USD 8.66 per share and pre-funded warrants for up to 3,226,458 shares at USD 8.659 per pre-funded warrant. The filing notes that the chief operating decision maker reviews cash, cash equivalents and marketable securities as a measure of segment assets. It also references a November 2025 sales agreement with Leerink Partners and a 2018 agreement with Gilead that included an initial upfront payment of USD 50.0 million.

Tango Therapeutics Q3 2026 Earnings: Key Takeaways

Tango Therapeutics reported a third quarter 2026 loss per share of USD 0.39. Research and Development expense was USD 48.9 million, general and administrative expense was USD 29.2 million, and cash, cash equivalents and marketable securities were USD 977.5 million.